Exenatide on GI Motor Function and Permeability in Short Bowel Syndrome

NCT01818648 on ClinicalTrials.gov · last registry update 2014-01-14

Withdrawn before anyone was enrolled. The sponsor logged completion for January 2014. Primary outcome, as filed: Change in 24hr Gastrointestinal and Colonic Transit before and after Exenatide vs placebo.

Status: WITHDRAWN
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: Mayo Clinic
Sponsor type: Other
Enrollment: 0
Started: 2013-03
Primary completion: 2014-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in 24hr Gastrointestinal and Colonic Transit before and after Exenatide vs placebo

Conditions studied

Short Bowel Syndrome

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.